Felicia Davatolhagh is a postdoctoral researcher at the University of California, Los Angeles in Anne Churchland’s lab, where she studies how cortical circuits are altered during decision-making in a genetic mouse model of autism. She also serves as a member of the neurobiology department’s Justice, Diversity and Inclusion (JEDI) group.
Felicia Davatolhagh
Postdoctoral researcher
University of California, Los Angeles
From this contributor
Women are systematically under-cited in neuroscience. New tools can change that.
An omitted citation in a high-profile paper led us to examine our own practices and to help others adopt tools that promote citation diversity.
Women are systematically under-cited in neuroscience. New tools can change that.
By
Anne Churchland, Felicia Davatolhagh
22 July 2024 | 5 min read
Explore more from The Transmitter
Measuring plastic in the brain: Improving, but incomplete
Meanwhile, researchers are publishing papers without “sufficient quality control,” says analytical chemist Dušan Materić.
Measuring plastic in the brain: Improving, but incomplete
Meanwhile, researchers are publishing papers without “sufficient quality control,” says analytical chemist Dušan Materić.
By
Amber Dance
18 September 2026 | 9 min read
Incredible shrinking grant deadlines at the BRAIN Initiative
“A month is crazy,” says one former recipient, referring to a new funding opportunity’s timeline.
Incredible shrinking grant deadlines at the BRAIN Initiative
“A month is crazy,” says one former recipient, referring to a new funding opportunity’s timeline.
By
Brendan Borrell
17 September 2026 | 4 min read
Sylvia Fogel, reshaping U.S. autism research strategy
In a wide-ranging and provocative interview, the chair of the federal Interagency Autism Coordinating Committee shares her views on vaccines, regression, neuroimmune conditions and more.
Sylvia Fogel, reshaping U.S. autism research strategy
In a wide-ranging and provocative interview, the chair of the federal Interagency Autism Coordinating Committee shares her views on vaccines, regression, neuroimmune conditions and more.
By
Brady Huggett
17 September 2026 | 77 min watch